COVID-19: DST funds start-up to scale up oxygenator production
DST funded start-up Genrich Membranes will scale up manufacturing of membrane oxygenator equipment (MOE) which enriches oxygen in the air up to 35% under pressure is very conducive in the treatment of COVID-19 infected patients
April 09, 2020
DST funded start-up Genrich Membranes will scale up manufacturing of membrane oxygenator equipment (MOE)
MOE helps enriching oxygen in the air up to 35%, supposed to be conducive for treatment of COVID-19 patients
MOE will take 3 months at least for coming up as a ready-to-use device
DST funded start-up Genrich Membranes will scale up manufacturing of membrane oxygenator equipment (MOE). This equipment enriches oxygen in the air up to 35% under pressure (4-7 bar, using oil-free compressor). MOE has been developed by CSIR-National Chemical Laboratory to treat COVID-19 patients
. Genrich Membranes is a spin-off company which is based on proprietary technology licensed from CSIR-National Chemical Laboratory, Pune. Now, Genrich Membranes is being funded by the Department of Science and Technology (DST) to scale up membrane oxygenator equipment.
The air that comes out as a product of MOE is of medical grade. MOE consists of membrane cartridge, oil-free compressor, output flowmeter, humidifier bottle, nasal-cannula, and tubing & fittings. The compressed, filtered air from the compressor is fed to the membrane cartridge, which selectively permeates oxygen over nitrogen offering oxygen-enriched air as the product at the ambient pressure. The membrane cartridge capable of distinguishing oxygen and nitrogen restricts the passage of viruses, bacteria, and particulate matter.
Conducive for COVID-19 patients
"Medical-grade oxygen-enriched air is needed in a variety of patient care settings including COVID-19 situations where the global experience is about 14% infections require some kind of respiratory support, but only about 4% need ICU based ventilators. The rest of this population, as well as in many other conditions involving chronic breathing problems, this innovation promises to be of excellent value", said Prof Ashutosh Sharma, Secretary, DST.
With an urgent requirement of respiratory interventions to treat breathlessness, one of the critical symptoms of COVID 19, the equipment can be used to treat patients who have been released from Intensive Care Units (ICU). The device can also be helpful for patients suffering from chronic breathing problems like Chronic Obstructive Pulmonary Disease (COPD), Asthma, Interstitial lung disease (ILD), pre-term babies, snake bite, and so on.
To be ready-to-use in 3 months
The testing and validation of Prototype have been demonstrated in a relevant environment and Genrich, the startup that has supported by DST- National Science & Technology Entrepreneurship Development Board (NSTEDB) Seed Support System and incubated by Entrepreneurship Development Center, (Venture Centre), Pune is planning to join hands with established medical device companies to mass manufacture MOE which can get this device ready, within three months.